Cargando…

Antiretroviral therapy response among HIV-2 infected patients: a systematic review

BACKGROUND: Few data are available on antiretroviral therapy (ART) response among HIV-2 infected patients. We conducted a systematic review on treatment outcomes among HIV-2 infected patients on ART, focusing on the immunological and virological responses in adults. METHODS: Data were extracted from...

Descripción completa

Detalles Bibliográficos
Autores principales: Ekouevi, Didier K, Tchounga, Boris K, Coffie, Patrick A, Tegbe, Joseph, Anderson, Alexandra M, Gottlieb, Geoffrey S, Vitoria, Marco, Dabis, François, Eholie, Serge P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156654/
https://www.ncbi.nlm.nih.gov/pubmed/25154616
http://dx.doi.org/10.1186/1471-2334-14-461
_version_ 1782333772633473024
author Ekouevi, Didier K
Tchounga, Boris K
Coffie, Patrick A
Tegbe, Joseph
Anderson, Alexandra M
Gottlieb, Geoffrey S
Vitoria, Marco
Dabis, François
Eholie, Serge P
author_facet Ekouevi, Didier K
Tchounga, Boris K
Coffie, Patrick A
Tegbe, Joseph
Anderson, Alexandra M
Gottlieb, Geoffrey S
Vitoria, Marco
Dabis, François
Eholie, Serge P
author_sort Ekouevi, Didier K
collection PubMed
description BACKGROUND: Few data are available on antiretroviral therapy (ART) response among HIV-2 infected patients. We conducted a systematic review on treatment outcomes among HIV-2 infected patients on ART, focusing on the immunological and virological responses in adults. METHODS: Data were extracted from articles that were selected after screening of PubMed/MEDLINE up to November 2012 and abstracts of the 1996–2012 international conferences. Observational cohorts, clinical trials and program reports were eligible as long as they reported data on ART response (clinical, immunological or virological) among HIV-2 infected patients. The determinants investigated included patients’ demographic characteristics, CD4 cell count at baseline and ART received. RESULTS: Seventeen reports (involving 976 HIV-2 only and 454 HIV1&2 dually reactive patients) were included in the final review, and the analysis presented in this report are related to HIV-2 infected patients only. There was no randomized controlled trial and only two cohorts had enrolled more than 100 HIV-2 only infected patients. The median CD4 count at ART initiation was 165 cells/mm(3), [IQR; 137–201] and the median age at ART initiation was 44 years (IQR: 42–48 years). Ten studies included 103 patients treated with three nucleoside reverse transcriptase inhibitors (NRTI). Protease inhibitor (PI) based regimens were reported by 16 studies. Before 2009, the most frequent PIs used were Nelfinavir and Indinavir, whereas it was Lopinavir/ritonavir thereafter. The immunological response at month-12 was reported in six studies and the mean CD4 cell count increase was +118 cells/μL (min-max: 45–200 cells/μL). CONCLUSION: Overall, clinical and immuno-virologic outcomes in HIV-2 infected individuals treated with ART are suboptimal. There is a need of randomized controlled trials to improve the management and outcomes of people living with HIV-2 infection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2334-14-461) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4156654
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41566542014-09-07 Antiretroviral therapy response among HIV-2 infected patients: a systematic review Ekouevi, Didier K Tchounga, Boris K Coffie, Patrick A Tegbe, Joseph Anderson, Alexandra M Gottlieb, Geoffrey S Vitoria, Marco Dabis, François Eholie, Serge P BMC Infect Dis Research Article BACKGROUND: Few data are available on antiretroviral therapy (ART) response among HIV-2 infected patients. We conducted a systematic review on treatment outcomes among HIV-2 infected patients on ART, focusing on the immunological and virological responses in adults. METHODS: Data were extracted from articles that were selected after screening of PubMed/MEDLINE up to November 2012 and abstracts of the 1996–2012 international conferences. Observational cohorts, clinical trials and program reports were eligible as long as they reported data on ART response (clinical, immunological or virological) among HIV-2 infected patients. The determinants investigated included patients’ demographic characteristics, CD4 cell count at baseline and ART received. RESULTS: Seventeen reports (involving 976 HIV-2 only and 454 HIV1&2 dually reactive patients) were included in the final review, and the analysis presented in this report are related to HIV-2 infected patients only. There was no randomized controlled trial and only two cohorts had enrolled more than 100 HIV-2 only infected patients. The median CD4 count at ART initiation was 165 cells/mm(3), [IQR; 137–201] and the median age at ART initiation was 44 years (IQR: 42–48 years). Ten studies included 103 patients treated with three nucleoside reverse transcriptase inhibitors (NRTI). Protease inhibitor (PI) based regimens were reported by 16 studies. Before 2009, the most frequent PIs used were Nelfinavir and Indinavir, whereas it was Lopinavir/ritonavir thereafter. The immunological response at month-12 was reported in six studies and the mean CD4 cell count increase was +118 cells/μL (min-max: 45–200 cells/μL). CONCLUSION: Overall, clinical and immuno-virologic outcomes in HIV-2 infected individuals treated with ART are suboptimal. There is a need of randomized controlled trials to improve the management and outcomes of people living with HIV-2 infection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2334-14-461) contains supplementary material, which is available to authorized users. BioMed Central 2014-08-26 /pmc/articles/PMC4156654/ /pubmed/25154616 http://dx.doi.org/10.1186/1471-2334-14-461 Text en © Ekouevi et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ekouevi, Didier K
Tchounga, Boris K
Coffie, Patrick A
Tegbe, Joseph
Anderson, Alexandra M
Gottlieb, Geoffrey S
Vitoria, Marco
Dabis, François
Eholie, Serge P
Antiretroviral therapy response among HIV-2 infected patients: a systematic review
title Antiretroviral therapy response among HIV-2 infected patients: a systematic review
title_full Antiretroviral therapy response among HIV-2 infected patients: a systematic review
title_fullStr Antiretroviral therapy response among HIV-2 infected patients: a systematic review
title_full_unstemmed Antiretroviral therapy response among HIV-2 infected patients: a systematic review
title_short Antiretroviral therapy response among HIV-2 infected patients: a systematic review
title_sort antiretroviral therapy response among hiv-2 infected patients: a systematic review
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156654/
https://www.ncbi.nlm.nih.gov/pubmed/25154616
http://dx.doi.org/10.1186/1471-2334-14-461
work_keys_str_mv AT ekouevididierk antiretroviraltherapyresponseamonghiv2infectedpatientsasystematicreview
AT tchoungaborisk antiretroviraltherapyresponseamonghiv2infectedpatientsasystematicreview
AT coffiepatricka antiretroviraltherapyresponseamonghiv2infectedpatientsasystematicreview
AT tegbejoseph antiretroviraltherapyresponseamonghiv2infectedpatientsasystematicreview
AT andersonalexandram antiretroviraltherapyresponseamonghiv2infectedpatientsasystematicreview
AT gottliebgeoffreys antiretroviraltherapyresponseamonghiv2infectedpatientsasystematicreview
AT vitoriamarco antiretroviraltherapyresponseamonghiv2infectedpatientsasystematicreview
AT dabisfrancois antiretroviraltherapyresponseamonghiv2infectedpatientsasystematicreview
AT eholiesergep antiretroviraltherapyresponseamonghiv2infectedpatientsasystematicreview